Biological Industries sponsors RegMedNet 2-month focus on the production of iPSCs

March 31, 2017 ( Induced pluripotent stem cells (iPSCs) are arguably one of the hottest topics within regenerative medicine. The first generation of iPSCs 10 years ago marked a huge milestone in the field, leading to great progress from disease modeling to development of new, personalized therapeutic approaches for numerous conditions. Key advantages include the potential low-cost manufacture of personalized medicines, omitting the need to use embryonic or fetal stem cells, efficiency of genetic manipulation compared with somatic cells and providing a source for cells that may otherwise have been difficult to obtain.

However, only one human trial using iPSCs has been carried out to date: in September 2014, a Japanese research team became the world’s first to commence a clinical trial using iPSCs, with autologous transplantation of iPSC-derived retinal cells. The trial was halted owing to safety concerns, but is set to recommence in 2017 – but it is key to note that this first patient was treated only 7 years after iPSCs were first discovered by Yamanaka, reflecting the speed that the iPSC field is progressing.

Biological Industries sponsors RegMedNet 2-month focus including journal articles, exclusive features, panel discussions and webinar events all in review of the current challenges in the production of iPSCs. Below you will find helpful resources from members of our Biological Industries USA technical team, Lia Kent and Dan Haus. Click the links below for the original posts.

Visit the RegMedNet spotlight page here.